Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class III · Low risk Terminated Initiated Dec 19, 2016 (10 years ago)

Aripiprazole Tablets

Class III — Low risk. Unlikely to cause harm, but violates FDA regulations.

Why it was recalled

Superpotent Drug: Product may not meet specifications throughout shelf life.

Cause type: Wrong potency / content

Sub- or super-potent product, or a failed content-uniformity / assay test. You may receive too little or too much active ingredient - a direct dosing risk. All wrong potency / content recalls.

What was recalled

Aripiprazole Tablets, 2 mg, 30-count bottle, Rx only, Manufactured by: Apotex Inc., Toronto, Ontario, Canada, M9L 1T9; Manufactured for: Apotex Corp., Weston, Florida 33326, NDC 60505-3075-3.

Affected NDC 60505-3075-03

Compare with the code on your package — it is the most precise check available.

Drug: Aripiprazole

Recalling firm
Apotex Inc.
NDC code
60505-3075-3
Origin
N/A, Canada
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0471-2017 · FDA notice

Low risk, still worth a check. Class III means the product is unlikely to cause harm but breaks an FDA rule (often labeling). If your lot matches, your pharmacy will normally swap it; there is no need for alarm. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Aripiprazole recalls

See all
Class II · Moderate risk

Aripiprazole Tablets USP

Product Mix-Up: A bottle containing Voriconazole Tablets 50 mg was labelled and distributed as Aripiprazole Tablets USP 30 mg.

Ongoing Labeling / mix-up Ajanta Pharma USA Inc NDC 27241-056-03 D-0594-2026
Class III · Low risk

Abilify (aripiprazole)

Cross Contamination with Other Products

Ongoing Cross-contamination Second Tokushima Factory, Otsuka Pharmaceutical Co., Ltd. NDC 59148-011-13 D-0469-2024
Class III · Low risk

Abilify (aripiprazole)

Cross Contamination with Other Products

Ongoing Cross-contamination Second Tokushima Factory, Otsuka Pharmaceutical Co., Ltd. NDC 59148-009-13 D-0468-2024
Class III · Low risk

Abilify (aripiprazole)

Cross Contamination with Other Products

Ongoing Cross-contamination Second Tokushima Factory, Otsuka Pharmaceutical Co., Ltd. NDC 59148-008-13 D-0467-2024

Other recalls by Apotex Inc.

All 2016 recalls
Class II · Moderate risk

Paxil CR

Failed Dissolution Specifications; product failed to meet 24-month stability testing acceptance criteria

Ongoing Dissolution failure Apotex Corp. NDC 60505-4379-3 D-0804-2026
Class II · Moderate risk

Desmopressin Nasal Spray

Defective container: defect in a batch of bottle caps, specifically involving dislodged or missing cap liners.

Ongoing Packaging defect Apotex Corp. NDC 60505-0815-0 D-0510-2026